Xenon Pharmaceuticals (STU:XP0) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 11, 2026)


STU:XP0 Xenon Pharmaceuticals Inc STU:XP0
20 GF Score
Price €60.00
GF Value €0.14
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xenon Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:XP0 vs DFTX, LEGN, TVTX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


STU:XP0
20GF Score
Xenon Pharmaceuticals Inc STU:XP0
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xenon Pharmaceuticals (STU:XP0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenon Pharmaceuticals stock appears to be overvalued. The current stock price of €60.00 is trading 42757.1% above its estimated GF Value™ of €0.14. GuruFocus considers Xenon Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:XP0:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €0.14 vs. price of €60.00 (42757.1% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the STU:XP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenon Pharmaceuticals Business Description

Other Exchanges XENE:USA
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
20GF Score

Get the complete analysis for STU:XP0

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.00
Price
€0.14
GF Value